Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial

NCT02577926 is registered in ClinicalTrials.gov with RWTH Aachen University as lead sponsor.

NCT NCT02577926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02577926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial
Lead sponsor
RWTH Aachen University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 31, 2015
Completion date
December 31, 2028
Enrollment
207 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia (et), polycythemia vera (pv)